Immunomodulatory effects of mesenchymal stem cells on B and T cells
Department of Biotechnology, RV College of Engineering, Bengaluru, Karnataka, India – 560059.
Review
World Journal of Biology Pharmacy and Health Sciences, 2023, 15(03), 006–010.
Article DOI: 10.30574/wjbphs.2023.15.3.0365
Publication history:
Received on 20 July 2023; revised on 31 August 2023; accepted on 03 September 2023
Abstract:
Mesenchymal stem cells (MSCs) or adult multipotent progenitor cells with the ability to self-renew and differentiate, are extracted from a variety of tissues, including bone marrow, adipose tissue, umbilical cord blood, Wharton’s jelly, tooth pulp, menstrual blood, and others. Since they are multipotent, cultured MSCs can differentiate into the adipogenic, chondrogenic, and osteogenic lineages after being isolated. Due to their immunomodulatory, immunosuppressive, and regenerative potentials, multipotent mesenchymal stem cells (MSCs) have received extensive scrutiny as an efficient tool for cell-based therapy of inflammatory, immune-mediated, and degenerative illnesses. Mesenchymal stem cells (MSCs) have been the subject of numerous preclinical and clinical research that looked into their therapeutic potential. This potential is primarily supported by MSCs' immunosuppressive characteristics. Even while there is still much to learn about the therapeutic characteristics of MSC transplantation, mounting evidence suggests that T and B cells undergo changes after MSC infusion, most notably the induction of regulatory T (Tregs) and B (Bregs) cells. Tregs and Bregs have been shown to exhibit immunosuppressive properties, and these cells are being considered as potential novel targets for the therapy of inflammatory disorders.
Keywords:
MSC; Immunomodulatory; T cells; B cells
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0